The significance of enhancer of zeste homolog 2 (EZH2) expression in spindle cell lesions of the breast

2021 ◽  
Author(s):  
Iskender Sinan Genco ◽  
Kayla Hackman ◽  
Doaa Morrar ◽  
Cao Jin ◽  
Eugene Santagada ◽  
...  
Keyword(s):  
Spindle Cell ◽  
Ezh2 Expression ◽  
Enhancer Of Zeste

scholarly journals A STUDY ON THE HISTONE METHYLTRANSFERASE ENHANCER OF ZESTE HOMOLOG 2 EXPRESSION IN BREAST CARCINOMA

2020 ◽  
pp. 66-68
Author(s):  
Rubaiya Ahmad ◽  
Syed Meraj Imam ◽  
Debarshi Jana
Keyword(s):  
Breast Carcinoma ◽  
Breast Tumor ◽  
Triple Negative ◽  
Histone Methyltransferase ◽  
Expression Level ◽  
High Grade ◽  
Over Expression ◽  
Ezh2 Expression ◽  
Triple Negative Breast Carcinoma ◽  
Enhancer Of Zeste

The over expression of EZH2 in Breast Carcinoma. Compare EZH2 expression in different immunophenotypes of breast carcinoma(basal, luminal, triple-negative). The study EZH2 expression level in association to staging and grading of breast carcinoma Patients attending the Dept of Pathology, Sri Krishna Medical Collage Muzaffarpur, Bihar with epithelial breast tumor. We found that EZH2 in Breast Carcinoma was significantly associated with grade of the tumour. EZH2 was significantly associated with stage of the tumour. It was found that EZH2 was significantly correlated with ki67 in Breast Carcinoma patients. Triple negative Breast Carcinoma patient was significantly associated with high grade of EZH2 tumour.

scholarly journals Enhancer of Zeste Homolog 2 Expression Is Associated With Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma: A Comparative Study and Review of the Literature

2013 ◽  
Vol 137 (10) ◽  
pp. 1326-1336 ◽  
Author(s):  
Bin Xu ◽  
Samuel Abourbih ◽  
Kanishka Sircar ◽  
Wassim Kassouf ◽  
Jose Joao Mansure ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Renal Cell ◽  
Clear Cell ◽  
Locally Advanced ◽  
Nuclear Grade ◽  
Primary Tumors ◽  
Pathologic Stage ◽  
Ezh2 Expression ◽  
Pathologic Features ◽  
Enhancer Of Zeste

Context.—Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase mediating chromatin condensation and epigenetic modulation, is overexpressed in various human carcinomas and is associated with adverse clinicopathologic characteristics and biologic behavior. The expression of EZH2 in renal cell carcinomas (RCCs) has not been fully characterized yet. Objective.—To evaluate the prognostic role of EZH2 in RCC by analyzing the immunohistochemical staining pattern of the marker in relation to pathologic features and clinical outcome. Design.—We correlated the immunolabeling of EZH2 with multiple clinicopathologic features, including Fuhrman nuclear grade, pathologic stage, metastatic status, and clinical outcome in 223 clear cell RCCs (CRCCs) and 21 papillary RCCs, by using tissue microarrays of primary and metastatic cases. Results.—Most CRCCs (75%) showed positive EZH2 staining, with most primary tumors showing focal staining in comparison to nonfocal staining in metastatic cases. In primary tumors, EZH2 expression was associated with higher nuclear grade and lower pathologic stage. Metastatic tumors showed a higher number of positive cases (81% versus 67%) and a more diffuse and more intense pattern of staining than primary CRCCs. For the 22 locally advanced primary tumors (T3/4) and 43 metastatic RCCs, patients who experienced RCC-related deaths significantly overexpressed the marker in comparison to patients who did not experience RCC-related mortality. Conclusions.—By showing that EZH2 expression is associated with increased metastatic potential and a worse clinical outcome, this study suggests that EZH2 can serve as a prognostic biomarker for RCC, thus confirming it as a key molecule driving oncogenesis and metastasis.

scholarly journals A repressive role of enhancer of zeste homolog 2 in 11β-hydroxysteroid dehydrogenase type 2 expression in the human placenta

2017 ◽  
Vol 292 (18) ◽  
pp. 7578-7587 ◽  
Author(s):  
Rujuan Zuo ◽  
Xiaohui Liu ◽  
Wangsheng Wang ◽  
Wenjiao Li ◽  
Hao Ying ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Histone H3 ◽  
Hydroxysteroid Dehydrogenase ◽  
Ezh2 Expression ◽  
Enhancer Of Zeste ◽  
E2f Transcription Factor ◽  
Pka Pathway ◽  
Transcription Factor 1

The expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which acts as a placental glucocorticoid barrier, is silenced in cytotrophoblasts but substantially up-regulated during syncytialization. However, the repressive mechanism of 11β-HSD2 expression before syncytialization and how this repression is lifted during syncytialization remain mostly unresolved. Here we found that enhancer of zeste homolog 2 (EZH2) accounts for the silence of 11β-HSD2 expression via trimethylation of histone H3 lysine 27 at the promoter of the 11β-HSD2 gene. Further studies revealed that, upon syncytialization, human chorionic gonadotropin reduced the phosphorylation of retinoblastoma protein (pRB) via activation of the cAMP/PKA pathway, which sequesters E2F transcription factor 1 (E2F1), the transcription factor for EZH2 expression. As a result of inactivation of the pRB-E2F1-EZH2 pathway, the repressive marker trimethylation of histone H3 lysine 27 at the 11β-HSD2 promoter is removed, which leads to the robust expression of 11β-HSD2 during syncytialization.

scholarly journals Ribophorin II is upregulated in myelodysplastic syndromes and prevents apoptosis and cell cycle progression

2020 ◽  
Vol 245 (12) ◽  
pp. 1009-1015
Author(s):  
Jinhai Ren ◽  
Ying Wang ◽  
Lihua Wang ◽  
Xiaoling Guo ◽  
Xiaonan Guo
Keyword(s):  
Cell Cycle ◽  
Cell Proliferation ◽  
Cell Cycle Arrest ◽  
Myelodysplastic Syndromes ◽  
Cell Apoptosis ◽  
Dependent Manner ◽  
Hematopoietic Stem ◽  
Cycle Arrest ◽  
Ezh2 Expression ◽  
Enhancer Of Zeste

Myelodysplastic syndromes (MDSs) are a series of heterogeneous diseases affecting hematopoietic stem cells that result in hematopoiesis disturbance and leukemic transformation. As an essential cell cycle regulator, ribophorin II (RPN2) has been extensively identified as a prospective predictor of prognosis in diverse malignant tumors. However, its effects on MDS are unclear. We observed increased mRNA expression RPN2 in samples from MDS patients, compared with samples from normal healthy controls. RPN2 overexpression promoted the proliferation of Ontario Cancer Institute OCI-acute myeloid leukemia 3 (OCI-AML3) cells, whereas RPN2 silencing clearly suppressed the proliferation of OCI-AML3 cells. Furthermore, RPN2 silencing caused G1/S cell cycle arrest and cell apoptosis. In addition, RPN2 overexpression led to a higher proportion of cells in the G2/M phase and reduced cell apoptosis. RPN2 overexpression downregulated enhancer of zeste homolog-2 (EZH2) expression, whereas RPN2 downregulation increased EZH2 expression in a dose-dependent manner. Co-immunoprecipitation showed an interaction between RPN2 and EZH2. Additionally, the administration of 3-deazaneplanocin A, an EZH2 inhibitor, reversed the function of RPN2 silencing in cell cycle arrest and apoptosis induction in OCI-AML3 cells. Hence, RPN2 is an essential regulator of cell proliferation. This study described the etiology of OCI-AML3 cell proliferation regulated by RPN2 and EZH2. Impact statement This study explored the role of ribophorin II (RPN2) in myelodysplastic syndromes (MDSs) cell proliferation and growth and revealed that RPN2 knockdown suppressed OCI-AML3 cell growth and proliferation and triggered cell cycle arrest and elicited apoptosis in OCI-AML3 cells. In addition, it shed light on the etiology of RPN2’s role in MDS cell proliferation that RPN2 can negatively impact enhancer of zeste homolog-2 (EZH2) expression, which in turn is able to modulate the cell cycle location and death in OCI-AML3 cells. Hence, RPN2 expression could be a latent predictor of prognosis in patients with MDS.

Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer

2016 ◽  
Vol 34 (6) ◽  
pp. 258.e1-258.e6 ◽  
Author(s):  
Joshua I. Warrick ◽  
Jay D. Raman ◽  
Matthew Kaag ◽  
Trey Bruggeman ◽  
Justin Cates ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Ezh2 Expression ◽  
Enhancer Of Zeste
Sign in / Sign up

Export Citation Format

Share Document